GLP-1s may not eliminate desire altogether, but they seem to weaken the reinforcing loop between anticipation and consumption, making it easier for patients to pause, reflect, and make healthier choices." Dr Sophie Dix, Head of Medical Product and Content at Levity "We hear all the time that our patients on GLP-1 medications have spontaneously reported drinking less, smoking less, or simply losing interest in previously compulsive behaviors
placebo), la mayora de ellos (liraglituda, semaglutida SC, dulaglutida, albiglutida y efpeglenatida) han demostrado adems una reduccin de los MACE respecto a placebo, mientras exenatida semanal o semaglutida oral mostraron una tendencia a reducir los MACE
Diabetes Ther 14 , 21732183 (2023)
the State Key Laboratory of Drug Research (SKLDR-2023-TT-04 to HEX)